Immuneering's Cash & cash equivalent grew by 40.84 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Immuneering's Quick Ratio to 5.45, Quick Ratio remained below Immuneering Corporation average.

Within Major Pharmaceutical Preparations industry 185 other companies have achieved higher Quick Ratio than Immuneering in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 307 to 695.

Explain Quick Ratio?
How much Cash & cash equivalents IMRX�s has?
What are IMRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IMRX/financial-strength

https://api.csimarket.com/api/v1/companies/IMRX/fundamentals

https://api.csimarket.com/api/v1/companies/IMRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

IMRX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	17.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-74.17 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	5.45	Subscribe	Subscribe	Subscribe	Subscribe
IMRX's Total Ranking	# 695	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	32.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	40.84 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 186
Healthcare Sector	# 297
Overall Market	# 695

Quick Ratio Statistics
High	Average	Low
40.42	16.36	3.7
(Mar 31 2022)		(Jun 30 2025)

Financial Statements
Immuneering's Current Liabilities	$ 11 Millions	Visit IMRX's Balance sheet
Immuneering's Cash & cash equivalent	$ 59 Millions	Visit IMRX's Balance sheet
Source of IMRX's Sales		Visit IMRX's Sales by Geography

Cumulative Immuneering's Quick Ratio

IMRX's Quick Ratio for the trailling 12 Months

IMRX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	18.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-15.17 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	8.24	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 95	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	5.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-37.91 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to IMRX Financial Strength Comparisons >> Go to Compare IMRX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $10.79 millions, cumulative Quick Ratio decreased to 8.24 below the Immuneering Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Immuneering. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2361 to 3174.

Explain Quick Ratio?
How much Cash & cash equivalents IMRX�s has?
What are IMRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 416
Healthcare Sector	# 847
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
18.77	11.98	5.31
(Jun 30 2022)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Sellas Life Sciences Group Inc	14.51	$ 134.711 Millions	$ 9.286 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions
Erasca Inc	13.10	$ 643.696 Millions	$ 49.122 Millions
Stablecoin Development Corporation	13.01	$ 7.153 Millions	$ 0.550 Millions
Uniqure N v	12.78	$ 768.430 Millions	$ 60.142 Millions
Rhythm Pharmaceuticals Inc	12.62	$ 320.944 Millions	$ 25.438 Millions
Assembly Biosciences Inc	12.61	$ 314.262 Millions	$ 24.921 Millions
Dyne Therapeutics Inc	12.53	$ 1,134.386 Millions	$ 90.545 Millions
Sensei Biotherapeutics Inc	12.44	$ 174.795 Millions	$ 14.049 Millions
Crescent Biopharma Inc	12.32	$ 289.357 Millions	$ 23.490 Millions
Spyre Therapeutics Inc	12.24	$ 82.727 Millions	$ 6.760 Millions
Edgewise Therapeutics inc	12.10	$ 1,743.893 Millions	$ 144.106 Millions
Obsidian Therapeutics, Inc.	11.77	$ 214.905 Millions	$ 18.264 Millions
Structure Therapeutics Inc	11.62	$ 1,244.661 Millions	$ 107.104 Millions
Immunome Inc	11.27	$ 461.582 Millions	$ 40.966 Millions
Korro Bio Inc	11.06	$ 165.015 Millions	$ 14.923 Millions
Xenon Pharmaceuticals Inc	10.99	$ 950.798 Millions	$ 86.487 Millions
Newamsterdam Pharma Company N v	10.99	$ 628.242 Millions	$ 57.154 Millions
Vtv Therapeutics Inc	10.99	$ 77.164 Millions	$ 7.024 Millions
Abcellera Biologics Inc	10.85	$ 764.424 Millions	$ 70.473 Millions
Cogent Biosciences Inc	10.82	$ 791.134 Millions	$ 73.118 Millions
Bicycle Therapeutics Plc	10.57	$ 469.928 Millions	$ 44.459 Millions
Lipocine Inc	10.55	$ 21.455 Millions	$ 2.034 Millions
Cyclerion Therapeutics Inc	10.32	$ 456.221 Millions	$ 44.197 Millions
Lexicon Pharmaceuticals Inc	10.31	$ 183.203 Millions	$ 17.773 Millions

Date modified: 2026-10-30T13:13:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.